IOVA vs LNTH
Iovance Biotherapeutics, Inc. vs Lantheus Holdings — AI-powered side-by-side comparison
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
VS
LNTH
Lantheus Holdings
67
Buy
| Metric | IOVA | LNTH |
|---|
| AI Score |
67
|
67
|
| Price |
$6.49
|
$100.63
|
| P/E Ratio |
-9.27×
|
23.91×
|
| ROE |
-56.0%
|
21.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
116.3%
|
60.1%
|
| Debt / Equity |
0.06×
|
0.44×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
79.2
|
42.5
|
| Beta |
0.701
|
-0.057
|
| Expected Upside |
—
|
+7.8%
|
AI Committee View
Current Innellis committee reasoning for IOVA versus LNTH.
The committee scores are tied.
IOVA and LNTH both score 67/100.
IOVA Committee View
67% agreement
6 analysts
The primary driver is revenue growing 34.5% yoy -- genuine top-line momentum. The main limiting factor is roe of only -40.5% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
LNTH Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical